Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Paying for Cancer Care Under the Diagnosis-Related Group Reimbursement

Paying for Cancer Care Under the Diagnosis-Related Group Reimbursement To the Editor.— I am writing in regard to the COMMENTARY entitled, "The Need for Diagnosis-Related Group 471," which appeared in the Feb 1, 1985, issue of JAMA.1 I, too, would like to see the patient care costs of clinical research paid for by Medicare. However, I believe the solution to this problem (creation of DRG [diagnosis-related group] 471) suggested by Yarbro and Mortenson is not properly focused. The prospective payment system using DRGs is a mechanism to pay for Medicare-covered services. Medicare was not meant to pay for clinical research, and Congress specifically excludes research from coverage. Before the Health Care Financing Administration can reimburse for a DRG 471, Congress must be convinced of the need to change the law. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Paying for Cancer Care Under the Diagnosis-Related Group Reimbursement

Altman, Stanley J.
JAMA , Volume 254 (8) – Aug 23, 1985
Download PDF
1 page

Paying for Cancer Care Under the Diagnosis-Related Group Reimbursement

Abstract



To the Editor.—
I am writing in regard to the COMMENTARY entitled, "The Need for Diagnosis-Related Group 471," which appeared in the Feb 1, 1985, issue of JAMA.1 I, too, would like to see the patient care costs of clinical research paid for by Medicare. However, I believe the solution to this problem (creation of DRG [diagnosis-related group] 471) suggested by Yarbro and Mortenson is not properly focused.
The prospective payment system using DRGs is a mechanism to pay for...
Loading next page...
 
/lp/american-medical-association/paying-for-cancer-care-under-the-diagnosis-related-group-reimbursement-sBbSJJILOb

References (1)

Publisher
American Medical Association
Copyright
Copyright © 1985 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1985.03360080042009
Publisher site
See Article on Publisher Site

Abstract

To the Editor.— I am writing in regard to the COMMENTARY entitled, "The Need for Diagnosis-Related Group 471," which appeared in the Feb 1, 1985, issue of JAMA.1 I, too, would like to see the patient care costs of clinical research paid for by Medicare. However, I believe the solution to this problem (creation of DRG [diagnosis-related group] 471) suggested by Yarbro and Mortenson is not properly focused. The prospective payment system using DRGs is a mechanism to pay for Medicare-covered services. Medicare was not meant to pay for clinical research, and Congress specifically excludes research from coverage. Before the Health Care Financing Administration can reimburse for a DRG 471, Congress must be convinced of the need to change the law.

Journal

JAMA – American Medical Association

Published: Aug 23, 1985

There are no references for this article.